For the roughly 100,000 Americans living with systemic sclerosis — a disease that slowly scars the body from within and offers no cure — science has long asked them to wait. Now, researchers at Cedars-Sinai have demonstrated in laboratory studies that an experimental synthetic RNA molecule called TY1 can not only halt but reverse the immune damage driving the disease, reducing organ scarring and restoring heart function in animal models. The work, born from cardiac research and now reaching toward a rare autoimmune condition, reminds us that the boundaries between diseases are often more perme
Experimental drug shows promise reversing systemic sclerosis in lab studies
Systemic sclerosis is a life-threatening autoimmune disease affecting approximately 100,000 people in the U.S., causing scarring of skin, lungs, heart and other organs.